Innospera Pharma
PrivateLast Round
Seed
May 1, 2025
Total Funding Raised
$5M
Momentum Score
25 /100
Company Overview
Innospera Pharma is a biotechnology company that develops small-molecule GPCR modulators for chronic inflammatory, metabolic, and fibrotic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Innospera Pharma Comps
Public and private peers based on sector, stage, and business model.
Innospera Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 1, 2025 |
Key People
Founding team and executive leadership
Innospera Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Seed |
| Seido Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 15, 2026
Monthly visitors increased 155% MoM.
- Jun 10, 2025
Dr. Glenn Crater appointed as the new Chief Medical Officer.
Innospera Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Innospera Pharma's valuation, stock price, and market status.
